Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk

Molecular Biology Reports

Volumn 39, Issue 4, 2012, Pages 4683-4690

  Shen, Su Qin ^a   Jiang, De Ke ^a   Liu, Guo Yuan ^a   Chen, Fang ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Gene polymorphism; Meta analysis; Ovarian cancer; P53 Codon 72

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MOLECULAR PATHOLOGY; ONCOGENE; OVARY CANCER; RISK ASSESSMENT; RISK REDUCTION; TP53 GENE; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; META ANALYSIS; OVARY TUMOR; PUBLISHING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; ARGININE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; PUBLICATION BIAS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863089109     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1260-x     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
3. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L et al (2007) Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23:367-376
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 Mutations in human cancers. Science 253:49-53
5. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J et al (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963
6. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D et al (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650-4656
7. Thomas M, Kalita A, Labrecque S, Pim D, Banks L et al (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100
8. Qie M, Zhang Y, Wu J (2002) Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao 33:274-275
9. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M et al (2006) Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100:173-178
10. Li T, Lu ZM, Guo M, Wu QJ, Chen KN et al (2002) p53 Codon 72 polymorphism (C/G) and the risk of human papillomavirusassociated carcinomas in China. Cancer 95:2571-2576
11. Pegoraro RJ, Moodley M, Rom L, Chetty R, Moodley J (2003) P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 13:444-449
12. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D et al (2004) P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13:277-280
13. Santos AM, Sousa H, Pinto D, Portela C, Pereira D et al (2006) Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 42:958-963
14. Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F et al (2006) Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 132:521-528
15. Jiang DK, Wang WZ, Ren WH, Yao L, Peng B et al (2011) TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol 131:220-228
16. Jiang DK, Ren WH, Yao L, Wang WZ, Peng B et al (2010) Metaanalysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 76(3):765.e1-7
17. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
19. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15-17
20. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629-634
21. Malisic E, Jankovic R, Slavkovic D, Milovic-Kovacevic M, Radulovic S (2010) p53 Gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia. J BUON 15:101-106
22. Santos AM, Sousa H, Portela C, Pereira D, Pinto D et al (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340:256-262
23. Gadducci A, Cristofano CD, Zavaglia M, Giusti L, Menicagli M et al (2006) P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 26:687-693
24. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM et al (2004) Effect of the codon 72 polymorphism (c.215G[C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24:21-34
25. Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG et al (2009) Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 69:2349-2357
26. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K et al (1997) The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239-245
27. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6:193-197
28. Hogdall EV, Hogdall CK, Christensen L, Glud E, Blaakaer J et al (2002) Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22:1859-1864
29. Kang S, Duan LH, Zhang JH, Guo W, Wang N et al (2004) Association of p53 gene polymorphism with susceptibility to ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 39:754-758
30. Jiang DK, Yao L, Wang WZ, Peng B, Ren WH et al (2011) TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World J Gastroenterol 17:1227-1233
31. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2010) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129:920-930
32. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
33. Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tsai HD et al (2002) The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril 77:43-45